Loading clinical trials...
Loading clinical trials...
The ipilimumab and nivolumab combination is now part of the standard of care for the treatment of melanoma, renal and lung cancer patients. Grade 3/4 adverse events (AEs) occur in 30 to 60% of patient...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Hospices Civils de Lyon
NCT06312137 · Non Small Cell Lung Cancer
NCT06594991 · Advanced Melanoma
NCT07005128 · Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
NCT07224425 · Solid Tumours, Melanoma
NCT07308106 · Non-small Lung Cancer
Groupement hospitalier Est - Multidisciplinary oncological platform
Bron
Hôpital Louis Pradel - Department of Pneumology
Bron
University hospital of Grenoble Alpes - Department of dermatology
Grenoble
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions